Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + BEAM
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Rituximab + BEAM is a high-dose chemotherapy conditioning regimen used before autologous stem cell transplantation (ASCT) for patients with relapsed or refractory lymphomas, particularly Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The regimen combines the anti-CD20 monoclonal antibody rituximab with the standard BEAM conditioning protocol (carmustine, etoposide, cytarabine, and melphalan). Rituximab is typically administered at a dose of 375mg/m² one day prior to beginning the standard BEAM high-dose chemotherapy. Studies have shown excellent outcomes for patients receiving this combination, with improved disease-free survival rates compared to BEAM alone in some patient populations.
- Other names
- rituximab with BEAM conditioning
02
Targets
Beyond the preview
Go deeper on rituximab + BEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + BEAM.